Buenos Aires, Argentina – Bioprofarma Bagó (a fully owned subsidiary of GRUPO EMPRESARIAL BAGO), today announced an exclusive licensing agreement with Polaris, a renowned American pharmaceutical company, to introduce ADI-PEG20 (ADZODI®), a novel treatment for Malignant Pleural Mesothelioma (MPM) to the LATAM. This partnership is set to improve the treatment landscape by delivering innovative therapeutic solution aimed at improving patient outcomes across the region.
Under the terms of this agreement, Polaris will develop and manufacture the product, and Bioprofarma Bagó will hold the marketing authorization rights and be responsible for registering, importing, and promoting it in the LATAM region.
The agreement enables Bioprofarma Bagó to enter this pathology, which has very few therapeutic alternatives, while also strengthening its position among demanding companies seeking partners capable of managing and maintaining agreements of this nature.
Leonardo Fernández, General Manager of Bioprofarma Bagó, stated: “We are excited about this collaboration with Polaris, a pioneer in advanced therapies. It is truly gratifying to have developed this project together and to ensure a promising future for both companies. I want to emphasize our responsible role as healthcare companies seeking to contribute to a worthy cause: helping patients find hope in ADZODI® for their treatment and recovery. We are thrilled to have shared our mutual trust on this first occasion, confident that we will continue to strengthen the links between innovation and access to high-value treatments”.
Steve Hsu, CEO of Polaris Pharmaceuticals, stated:
“We are very excited about this partnership with Bioprofarma Bagó s as one of leading pharmaceutical companies in the LATAM region. This partnership not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology and rare disease treatments. This collaboration with Bioprofarma Bagó reflects Polaris’s ideal strategic partnership model to bring new treatment options to people living with serious cancer diseases.”.
About Polaris:
Polaris Group is a biopharmaceutical company dedicated to pioneering advanced therapies, primarily focusing on metabolic-related diseases. Our lead drug candidate, ADI-PEG 20 (ADZODI®), is presently advancing through the BLA-enabling stage for MPM and clinical development for other indications. ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. ADI-PEG20 is designed to disrupt cancer cell metabolism, providing a novel approach to treating a wide range of cancers heavily influenced by metabolic pathways. Our mission is to revolutionize the treatment of complex diseases like cancer by concentrating on their metabolic foundations, ultimately striving to enhance patient outcomes globally. https://www.polarispharma.com
Our goal is to continue working so that more patients in the region have the opportunity to access the most innovative treatments at the same time as those in more developed countries.
Bioprofarma Bagó
Working the present, thinking the future.
